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INTRODUCTION
 Chronic Obstructive Pulmonary Disease is a 
systemic disease characterized by the irreversible 
airflow obstruction. The airflow restriction is an 
abnormal inflammatory response occurring in the 
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lungs against harmful particles and gases in the 
inhaled air.1 COPD is one of the leading causes 
of chronic morbidity and mortality worldwide1 
the mortality due to this disease is increasing 
rapidly, making it third leading cause of death 
by 2020.2 COPD is preventable and treatable. 
Once considered primarily a pulmonary disease, 
it is now associated with a variety of systemic 
manifestations. It is characterized by low grade 
chronic inflammatory response in the body which 
is associated with several metabolic effects and 
systemic complications.3 One of the grave metabolic 
associations of any chronic inflammatory activity is 
insulin resistance.4,5
 Insulin resistance is one of the leading 
metabolic and endocrine problems in the world. 
It is the mechanism behind and association in 
the manifestations of obesity6, dyslipidemias, 
cardiovascular6 and cerebrovascular morbidities 
and mortalities. In a recent study, it has been 
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ABSTRACT
Objective: To compare mean homeostatic model assessment of insulin resistance (HOMA-IR) in patients 
with and without chronic obstructive pulmonary disease (COPD).
Methods: A Case control analytic study was conducted in medical outpatient department of Medial Unit-II 
of Dow University of Health Sciences from April 2013 to September 2013. All patients with the diagnosis 
of COPD were included as cases. Controls were age match healthy individuals with minor illnesses. Age, 
weight, height and forced expiratory volume in one second to forced vital capacity (FEV1/FVC) ratio were 
documented. Fasting blood glucose and fasting insulin levels were done. Body mass index (BMI) and IR was 
calculated using the formulas. HOMA-IR was compared between cases and controls.
Results: Forty COPD patients were compared with thirty five age match controls. HOMA-IR was found to be 
higher in cases as compared to controls (2.85 v/s 2.00) with a p value <0.000.
Conclusion: COPD is one of the chronic debilitating diseases in our region with various extra-pulmonary 
complications. We found IR to be present higher in COPD patients compared with healthy controls. 
Evaluating the pulmonary function as well as systemic metabolic parameters, may contribute to minimizing 
mortality and morbidity.
KEY WORDS: BMI, Chronic obstructive pulmonary disease, HOMA-IR, Insulin resistance.
doi: http://dx.doi.org/10.12669/pjms.316.7983
How to cite this:
Kiran Z, Majeed N, Zuberi BF. Comparison of frequency of insulin resistance in patients with chronic obstructive pulmonary disease 
with normal controls. Pak J Med Sci 2015;31(6):1506-1510.   doi: http://dx.doi.org/10.12669/pjms.316.7983
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
   Pak J Med Sci   2015   Vol. 31   No. 6      www.pjms.com.pk   1507
Insulin resistance in COPD versus healthy controls
suggested to be associated with the progression of 
vascular endothelial dysfunction in patients with 
COPD.7 In one study, IR has been found to be higher 
in patients with COPD compared with healthy age-
matched controls.8 It has been speculated that IR is 
a risk factor for the development of atherosclerotic 
cardiac disease and even type 2 diabetes mellitus in 
the future in patients with COPD.8 Moreover, it is 
independent of the severity of airway obstruction 
suggesting its early occurrence in the disease 
process.3 Thus, insulin resistance carries higher 
risk for metabolic and cardiovascular diseases in 
patients with COPD even when clinically stable.3
 This study compares insulin resistance as mean 
HOMA-IR in patients with and without chronic 
obstructive pulmonary disease in the region of 
Pakistan. There is no study in our region about 
the association of IR in COPD patients, which is 
a public concern. Therefore, apart from assessing 
lung functions in patients with COPD, evaluating 
their associated conditions like insulin resistance 
will lead to better management and quality of life 
in these patients.
METHODS
 The study was conducted at Medial Unit-II of 
Dow University of Health Sciences from April 
2013 to September 2013. All patients who were 
attending medical outpatient departmentwith 
the diagnosis of COPD for more than one year, 
according to the updated American Thoracic 
Society/European Respiratory Society (ATS/
ERS) 9 and Global Initiative for Chronic 
Obstructive Lung Disease (GOLD)1 guidelines 
were considered. Only those subjects were 
included in the study which fitted the following 
inclusion criteria: A post-bronchodilator forced 
expiratory volume in one second (FEV1)/forced 
vital capacity (FVC) < or equal to 0.7 confirming 
the presence of airflow limitation that is not fully 
reversible. They were further classified by the 
same criteria into four groups; mild (FEV1%pred 
≥80), moderate (FEV1%pred 50-80), severe 
(FEV1%pred 30-50) and very severe (FEV1%pred 
<30). Patients with following conditions were 
excluded from the study: obstructive airways 
disease other than COPD (bronchiectasis, cystic 
fibrosis or fibrosis due to tuberculosis), smoking 
within the last one month, patients on steroids, 
known thyroid diseases, hypercortisolism, 
diabetes mellitus, hyperlipidemias, ischemic heart 
disease, non-pulmonary infective diseases, renal, 
cardiac or hepatic failures, autoimmune diseases 
and malignancies. Ethical approval was sought 
from ethics review committee of the institute 
(IRB-370/DUHS-13). A case control analysis was 
conducted in the total of forty patients who fitted 
in our criteria and were hence enrolled in the 
study after performing spirometry and taking 
informed consent. Thirty five age-matched healthy 
controls attending OPD with minor illnesses like 
gastroenteritis and viral flu were enrolled after 
taking informed consent.
 Data was collected for age, gender, weight and 
height and FEV1/FVC ratio. Body Mass Index (BMI) 
was calculated and patients allocated to normal, 
under or overweight categories accordingly. 
Fasting blood samples were obtained by cubital 
venipuncture and then transferred to a single 
laboratory for analysis. Plasma fasting glucose level 
was measured enzymatically using an automated 
analyzer. Fasting plasma insulin were measured 
by radioimmunoassay. Insulin resistance was 
determined for all patients using HOMA-IR, where 
HOMA-IR = fasting glucose (mg/dl) x fasting 
insulin (mU/L)/ 405.10The pulmonary function 
tests of all individuals were performed according to 
the criteria recommended by European Respiratory 
Society, using a computer-associated spirometer 
device (Vmax22D, Sensor Medics, California; USA). 
FVC, FEV1 and FEV1/FVC ratio were measured 
and absolute values and predicted percent of these 
parameters were evaluated. The best three tests 
were recorded.11
Statistical Analysis: Data analysis was done 
using SPSS version 18.0. Descriptive statistics 
were calculated for all continuous variables. Mean 
+/- Standard Deviation (SD) was calculated for 
age, weight, height, BMI, fasting blood glucose 
levels and fasting Insulin levels. Frequencies 
& percentages for categorical variables were 
calculated. BMI and HOMA-IR with and without 
COPD between two groups were compared using 
T test. P-value ≤ 0.05 was taken as statistically 
significant.
RESULTS
 Forty cases of COPD (23 males and 17 females) 
and thirty five age match healthy controls (21 
males and 14 females) were enrolled in the study. 
The age ranged from a minimum of 26 years and 
maximum of 60 years with a mean of 40.88 years 
± 11.127 years. Body Mass Index was calculated 
as weight (in Kg) per height (in meters) squared. 
Mean BMI was calculated to be 24.96 Kg/
m2±5.65in cases and 25.19 Kg/m2±5.54in controls 
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with no difference between the two groups (p 
value=0.978). However, overall participants were 
more overweight in both groups [27 (67.50%) of the 
COPD patients and 24 (60%) of the controls].The 
characteristics of the two study groups are shown 
in Table-I. Patients with COPD were divided 
into four groups by the severity of their disease 
according to the guidelines.1There were no patients 
with mild or very severe severities. Thirty patients 
(75%) had moderate COPD and only ten (25%) 
were found to be severe. HOMA-IR was calculated 
for all patients and found to be higher among cases 
as compared to controls (Mean 2.85 v/s 2.00) with 
a significant difference noted statistically (60% 
v/s 14.28%, p value=0.000).Comparing each BMI 
category of total number of patients showed that 
BMI status does not affect the presence of insulin 
resistance as there are more overweight patients 
without insulin resistance (p value=0.038) as 
shown in Table-II. Statistical comparison among 
independent variables between two groups is 
shown in the Table-III. An important observation is 
that Fasting glucose levels have shown significant 
difference between the two groups (p value=0.011) 
which is an independent factor.
DISCUSSION
 Chronic Obstructive Pulmonary Disease is 
recently recognized to have clear extra-pulmonary 
effect.12,13 There is a well-known association of 
COPD with excess risk of cardiovascular disease 
and type 2 diabetes.3 Epidemiological data and 
several retrospective studies suggest that diabetes 
mellitus is much more common in patients with 
COPD than in healthy controls.14,15 Similarly, a 
recent observational study has also shown higher 
prevalence of metabolic syndrome in patients 
with COPD than in healthy subjects (57% v/s 
40%).16 In fact, studies have shown that mortality 
in patients with COPD is mainly due to non-
respiratory disorders such as cardiovascular 
diseases rather than the airway disease itself.17 
Systemic inflammation has a clear association 
with the presence of metabolic syndrome in COPD 
patients.17 This systemic inflammation associated 
with COPD is an important concept behind various 
metabolic and cardiovascular outcomes in these 
patients.3,18 
 One of the major systemic effects of such a chronic 
inflammatory condition is insulin resistance.5 
Insulin resistance is a growing pandemic all over 
the world. It is an important marker of metabolic 
syndrome in general, and is an independent risk 
factor for its cardiovascular complications. Systemic 
inflammation promotes IR, which in turn contributes 
to the development of metabolic syndrome in 
people with COPD.3 In developed regions, studies 
have also been carried out regarding various 
metabolic and inflammatory markers being present 
even in stable COPD patient population who 
Zareen Kiran et al.
Table-I: Characteristics of the control group and COPD cases.
 Cases N=40 Controls N=35
Age (years) 40.88 (SD±11.12) 41.9 (SD±11.7)
Sex Male=23, Female=17 Male=21, Female=14
BMI 24.96 Kg/m2  (SD± 5.65) 25.19 Kg/m2  (SD± 5.54)
Disease stage Moderate COPD = 30 (75%)
 Severe = 10 (25%) -
Table-III: Statistical comparison among independent variables between two groups.
 Control Cases (COPD) P value
 Mean (SD) Mean (SD)
Fasting blood glucose (mg/dl) 89 (13.70) 98.13 (10.24) 0.011
Fasting insulin level 9.35 (2.92) 12.04 (4.75) -
BMI 25.2 (5.55) 24.96 (5.65) 0.978
HOMA-IR 2.01(0.61) 2.86 (1.09) 0.000
FEV1/FVC 85.52 (5.53) 56.67 (10.48) -
Table-II: Comparison of BMI groups
with Insulin resistance.
BMI category      Insulin Resistance P value
 Absent (n) Present (n)
Underweight 7 0 0.038
Normal 12 5
Overweight 27 24
Total   46 29
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have established metabolic syndrome.13A recent 
observational multicenter study has measured 
various components of metabolic syndrome to be 
more frequent in COPD patients with prevalence 
of diabetes, osteoporosis, coronary artery disease 
and heart failure increasing their morbidity and 
mortality.1 Insulin resistance itself is also found to be 
present even in stable COPD patients because of the 
characteristic low grade inflammation [mean(SD), 
3.71(3.63) vs. 1.83(1.17)].8
 Comparative studies have demonstrated 
increased level of IR in COPD patients with 
metabolic syndrome than those without metabolic 
syndrome, reflecting prognostic significance in 
this subgroup with regards to their cardiovascular 
and metabolic outcomes.19,20 This finding however 
cannot be independently explained due to the 
chronic nature of the disease process and its 
underlying chronic inflammation, requiring more 
extensive research in this regard, especially in our 
population, because future therapies are now being 
considered to direct towards targeted inflammatory 
markers for appropriate management of this patient 
population.18 More recently, a cross sectional study 
from the National Health and Nutrition Evaluation 
Survey (NHANES) data set (2007–2010) has also 
identified many associated factors, including 
insulin resistance which has a direct contribution to 
the development of metabolic syndrome in patients 
with COPD.21Naik et al explicitly explained that 
various metabolic factors are linked with COPD. 
These factors are contributing the pathogenic 
variety needing special attention.22 Therefore, as an 
essential part of the spectrum, still a direct effect of 
IR on the patients with COPD independent of other 
metabolic and inflammatory markers would remain 
an area of research as IR is a dynamic connection 
between a chronic inflammatory process like COPD 
and metabolic derangements.
 However, no study has compared an independent 
association of IR in patients with COPD regardless 
of other metabolic markers with healthy controls. In 
a third world country like Pakistan, where COPD 
patient population is an important health care 
figure on the government and its policies, there is 
no study regarding its association with IR or any 
other metabolic parameters with its consequent 
effects on cardiovascular and endocrine outcomes. 
Moreover, studies are required to see the effect of 
managing IR as well as various other metabolic 
parameters in patients with COPD apart from their 
respiratory profiles to improve the morbidity and 
mortality.
 Our study compares the presence of HOMA-IR 
in patients with COPD with healthy age matched 
controls. There was no difference in the BMI groups, 
with greater frequency of being overweight in both 
study populations. Therefore, insulin resistance 
was found to have an independent association 
with COPD patients regardless of other metabolic 
parameters. A recent retrospective observational 
analysis of such outpatient population of COPD 
has shown higher prevalence of diabetes mellitus 
with higher BMI and use of corticosteroids as an 
associated factor which might be contributing15, 
but our study has excluded such confounding 
factor. However, fasting blood sugar and fasting 
insulin levels were higher in the COPD patients as 
compared to healthy controls. This is an important 
independent finding which needs further research 
because this has directly affected the calculated 
insulin resistance which is higher among COPD 
patients (2.85 v/s 2.00, p value <0.000). Whether 
this reflects the finding of the general population 
is an area of controversial debate, as our sample 
size was small, which was a limitation to our study. 
The reason being the strict exclusion criteria to take 
control on confounders of insulin resistance and a 
justification of small size as well.Another important 
limitation is that our healthy control population 
was not ideal controls, which was due to our ethical 
consideration to population sampling.
CONCLUSION
 Insulin resistance is found to be higher in patients 
with COPD even when stable, compared with 
healthy controls in our tertiary setup. In the light of 
its well-known contribution to metabolic syndrome 
in this chronic disease and its progressive risk to 
cause type 2 diabetes and cardiovascular morbidity, 
it needs to be evaluated along with other markers in 
further studies. Moreover, it may be emphasized to 
evaluate COPD patients far beyond their respiratory 
condition, during their follow up as this may have 
impact on their health care outcomes.
Disclosure: Authors have no conflict of interest.
Grant Support & Financial Disclosures: None.
REFERENCES
1. Global Strategy for the Diagnosis Management, 
and Prevention of Chronic Obstructive Pulmonary 
Disease. Global Initiative for Chronic Obstuctive Lung 
Disease(GOLD). 2010. Available from: http://www.
goldcopd.org/
Insulin resistance in COPD versus healthy controls
2. Murray CJL, Lopez AD. Alternative projections of mortality 
and disability by cause 1990–2020: Global Burden of Disease 
Study. Lancet. 1997;349:1498-1504.doi: 10.1016/s0140-
6736(96)07492-2
3. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, 
Dunseath G, et al. Insulin resistance and inflammation - A 
further systemic complication of COPD. COPD. 2007;4:121-
126.doi: 10.1080/15412550701341053
4. Ji ZZ, Dai Z, Xu YC. A new tumor necrosis factor (TNF)-
alpha regulator, lipopolysaccharides-induced TNF-alpha 
factor, is associated with obesity and insulin resistance. 
Chin Med J (Engl). 2011;124:177-182.
5. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo 
M, et al. Angiopoietin-like protein 2 promotes chronic 
adipose tissue inflammation and obesity-related systemic 
insulin resistance. Cell Metab. 2009;10:178-188.doi:10.1016/j.
cmet.2009.08.003
6. de Vries R, Kappelle PJ, Dallinga-Thie GM, Dullaart 
RP. Plasma phospholipid transfer protein activity is 
independently determined by obesity and insulin resistance 
in non-diabetic subjects. Atherosclerosis. 2011;217(1):253-
259. doi: 10.1016/j.atherosclerosis.2011.03.021
7. Urban MH, Ay L, Funk  GC, Burghuber OC, Eickhoff 
P, Wolzt M, et al. Insulin resistance may contribute 
to vasculardysfunction in patients with chronic 
obstructivepulmonary disease. Wien KlinWochenschr. 
2014;126:106–112.
8. Eker S, Ayaz L, Tamer L, Ulubas B. Leptin, visfatin, insulin 
resistance, and body composition change in chronic 
obstructive pulmonary disease. Scand J Clin Lab Invest. 
2010;70:40-44.doi: 10.3109/00365510903484063
9. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist 
AS, et al. Standards for the diagnosis and treatment 
of patients with COPD: a summary of the ATS/ERS 
position paper. EuroRespiratory J. 2004;23:932-946.doi: 
10.1183/09031936.04.00014304
10. Vasques AC, Rosado LE, Cassia GR, Geloneze B. Critical 
analysis on the use of the homeostasis model assessment 
(HOMA) indexes in the evaluation of the insulin resistance 
and the pancreatic beta cells functional capacity. Arq Bras 
EndocrinolMetabol. 2008;52:32-39.
11. Laszlo G. Standardisation of lung function testing: 
helpful guidance from the ATS/ERS Task Force. Thorax. 
2006;61:744-746.doi: 10.1136/thx.2006.061648
12. Clini E, Crisafulli E, Radaeli A, Malerba M. COPD and 
the metabolic syndrome: an intriguing association. Intern 
Emerg Med. 2013;8:283-289.doi: 10.1007/s11739-011-0700-x
13. Akpinar EE, Akpinar S, Ertek S, Sayin E, Gulhan M. 
Systemic inflammation and metabolic syndrome in stable 
COPD patients. TuberkToraks. 2012;60:230-237.
14. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson 
JE. Prevalence of major comorbidities in subjects with 
COPD andincidence of myocardial infarction and stroke: 
a comprehensiveanalysis using data from primary care. 
Thorax. 2010;65(11):956–962.
15. Paola R, Luigino C, Andrea S, Annapina B, Mario C. 
Diabetes mellitus among outpatients with COPD attendinga 
university hospital. ActaDiabetol. 2014;51(6):933-940. 
doi: 10.1007/s00592-014-0584-0
16. Breyer M-K, Spruit MA, Hanson CK, Franssen FME, 
Vanfleteren LEGW, et al. Prevalence of Metabolic Syndrome 
in COPD patients and itsconsequences.PLoS ONE. 
2014;9(6):e98013. doi: 10.1371/journal.pone.0098013
17. Stanciu S, Marinescu R, Iordache M, Dumitrescu S, Muresan 
M, Bogdan MA. Are systemic inflammatory profiles 
different in patients with COPD and metabolic syndrome 
as compared to those with COPD alone? Rom J Intern Med. 
2009;47:381-386.
18. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, 
Meyer T, et al. The metabolic syndrome in patients with 
chronic bronchitis and COPD: frequency and associated 
consequences for systemic inflammation and physical 
inactivity. Chest. 2009;136:1039-1046.doi: 10.1378/
chest.09-0393
19. Diez-Manglano J, Barquero-Romero J, Almagro P, Cabrera 
FJ, Lopez Garcia F, Montero L, et al. COPD patients with 
and without metabolic syndrome: clinical and functional 
differences. Intern Emerg Med. 2014;9(4):419-425.doi: 
10.1007/s11739-013-0945-7
20. Minas M, Kostikas K, Papaioannou AI, Mystridou P, 
Karetsi E, Georgoulias P, et al. The association of metabolic 
syndrome with adipose tissue hormones and insulin 
resistance in patients with COPD without co-morbidities. 
COPD. 2011;8:414-420.doi: 10.3109/15412555.2011.619600
21. Park SK, Larson JL. Metabolic syndrome and associated 
factors in people with chronic obstructive pulmonary 
disease. Western JNursRes. 2014;36(5):620-642.
22. Naik D, Joshi A, Paul TV, Thomas N. Chronic obstructive 
pulmonary disease and the metabolic syndrome: 
Consequences of a dual threat. Indian J Endocrinol Metab. 
2014;18(5):608-616.
Authors’ Contribution:
ZK: Conceived, designed, did patient examination, 
data collection and manuscript writing.
NM: Designed, did statistical analysis and initial 
review.
BFZ: Supervised the study, did final review and 
editing of manuscript.
Zareen Kiran et al.
1510   Pak J Med Sci   2015   Vol. 31   No. 6      www.pjms.com.pk
